Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Gemtuzumab Ozogamicin (GO)
DRUG
4 trials
Sponsors
Eastern Cooperative Oncology Group
, Versailles Hospital
, Brown University
Conditions
Acute Myeloid Leukemia
Leukemia
Leukemia, Myeloid, Acute
Phase 1
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
Completed
NCT03374332
Brown University
Acute Myeloid Leukemia
Start: 2019-12-31
End: 2025-03-31
Updated: 2026-07-23
Phase 2
Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4
Completed
NCT02473146
Versailles Hospital
Acute Myeloid Leukemia
Start: 2015-11-18
End: 2023-09-07
Updated: 2024-02-02
Phase 3
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Completed
NCT00049517
Eastern Cooperative Oncology Group
Leukemia
Start: 2002-12-19
End: 2019-12-31
Updated: 2023-06-15
Unknown Phase
Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®
NCT03287128
Versailles Hospital
Leukemia, Myeloid, Acute
Start: 2017-11-01
End: 2019-03-01
Target: 300
Updated: 2018-01-24
Related Papers
Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
Blood
2023-11-02
Characteristics and prognostic impact of<i>IDH</i>mutations in AML: a COG, SWOG, and ECOG analysis
Blood Advances
2023-06-02
50 citations
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG‐ACRIN analysis
Cancer
2023-04-25
8 citations
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling
Leukemia Research
2022-10-21
7 citations
Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study
Blood
2021-11-05
5 citations
Prognostic Significance of <i>DDX41</i> Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study
Blood
2021-11-05
1 citations
Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin
Blood
2021-11-05
1 citations
BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
Blood
2019-11-13
1 citations
Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)
Blood
2018-11-29
ANTHRACYCLINE DOSE INTENSIFICATION IN DIFFUSE LARGE <scp>B</scp>‐CELL LYMPHOMA
Hematological Oncology
2017-06-01
A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia.
2016-06-01
15 citations
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
Blood
2016-01-11
127 citations
Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia
Blood
2014-12-06
Anthracycline dose intensification in acute myeloid leukemia.
2009-09-01
687 citations